Sanofi SNY
NASDAQ
| 06/30/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | 49.45B | 47.55B | -- | |
| Total Other Revenue | -- | 3.50B | 3.36B | -- | |
| Total Revenue | -- | 52.95B | 50.92B | -- | |
| Cost of Revenue | -- | 14.65B | 14.24B | -- | |
| Gross Profit | -- | 38.30B | 36.68B | -- | |
| SG&A Expenses | -- | 10.93B | 10.47B | -- | |
| Depreciation & Amortization | -- | 2.01B | 1.87B | -- | |
| Other Operating Expenses | -- | 5.77B | 5.34B | -- | |
| Total Operating Expenses | -- | 42.25B | 40.53B | -- | |
| Operating Income | -- | 10.70B | 10.38B | -- | |
| Income Before Tax | -- | 6.74B | 8.97B | -- | |
| Income Tax Expenses | -- | 1.16B | 1.71B | -- | |
| Earnings from Continuing Operations | -- | 5.58K | 7.25K | -- | |
| Earnings from Discontinued Operations | -- | 3.25B | 3.04B | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -41.80M | -46.45M | -- | |
| Net Income | -- | 8.79B | 10.25B | -- | |
| EBIT | -- | 10.70B | 10.38B | -- | |
| EBITDA | -- | 14.57B | 13.10B | -- | |
| EPS Basic | -- | 7.19 | 8.38 | -- | |
| Normalized Basic EPS | -- | 2.03 | 1.01 | -- | |
| EPS Diluted | -- | 7.19 | 8.38 | -- | |
| Normalized Diluted EPS | -- | 2.03 | 1.01 | -- | |
| Average Basic Shares Outstanding | -- | 4.88B | 4.92B | -- | |
| Average Diluted Shares Outstanding | -- | 4.88B | 4.92B | -- | |
| Dividend Per Share | -- | 4.80 | 4.18 | -- | |
| Payout Ratio | -- | 124.88% | 52.84% | -- | |